TY - JOUR T1 - Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma JF - In Vivo JO - In Vivo SP - 2647 LP - 2652 DO - 10.21873/invivo.12083 VL - 34 IS - 5 AU - KAZUO KOBAYASHI AU - YUSUKE IIKURA AU - MAKOTO HIRAIDE AU - TAKASHI YOKOKAWA AU - TAKESHI AOYAMA AU - SARI SHIKIBU AU - KOKI HASHIMOTO AU - KENICHI SUZUKI AU - HITOSHI SATO AU - ERIKA SUGIYAMA AU - MASATAKA TAJIMA AU - TOSHIHIRO HAMA Y1 - 2020/09/01 UR - http://iv.iiarjournals.org/content/34/5/2647.abstract N2 - Background/Aim: Immune-related adverse events (irAEs) are associated with the efficacy of immune-checkpoint inhibitors in patients with melanoma and non-small cell lung cancer. We therefore evaluated the relationship between irAEs and nivolumab efficacy against metastatic renal cell carcinoma. Patients and Methods: The medical records of 53 consecutive patients were reviewed and analyzed. Results: Median overall survival was significantly better in patients who showed irAEs at any time compared to patients without irAEs (p=0.013). We identified irAEs in 24 of 53 patients (45.3%), including four patients (7.5%) with grade 3 events. Multivariate analysis also revealed that risk factors for the onset of irAEs were positively associated with a platelet-to-lymphocyte ratio <156 before nivolumab treatment (p=0.006). Conclusion: Development of irAEs was associated with survival outcomes of nivolumab treated patients with metastatic renal cell carcinoma. ER -